Azarga Dosage/Direction for Use

Posology: Use in adults, including the elderly: The dose is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily.
When using nasolacrimal occlusion or closing the eyelids, systemic absorption is reduced. This may result in a decrease in systemic side effects and increase in local activity (see Precautions).
If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) twice daily.
When substituting another ophthalmic antiglaucoma medicinal product with AZARGA, the other medicinal product should be discontinued and AZARGA should be started the following day.
Special populations: Paediatric population: The safety and efficacy of AZARGA in children and adolescents aged 0 to 18 years have not yet been established. No data are available.
Hepatic and renal impairment: No studies have been conducted with AZARGA eye drops in patients with hepatic or renal impairment. No dosage adjustment is necessary in patients with hepatic impairment or in patients with mild to moderate renal impairment.
AZARGA has not been studied in patients with severe renal impairment (creatinine clearance <30 ml/min) or in patients with hyperchloraemic acidosis (see Contraindications). Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZARGA is therefore contraindicated in patients with severe renal impairment (see Contraindications).
AZARGA should be used with caution in patients with severe hepatic impairment (see Precautions).
Method of administration: For ocular use.
Patients should be instructed to shake the bottle well before use. After cap is removed, if tamper evident snap collar is loose, remove before using product.
To prevent contamination of the dropper tip and the suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Instruct patients to keep the bottle tightly closed when not in use.
If more than one topical ophthalmic medicinal product is used, the medicinal products must be administered at least 5 minutes apart.Eye ointments should be administered last.